In a 53-year-old female who was on phenytoin 100 mg twice daily and started levetiracetam 500 mg twice daily one week ago, now presenting with dizziness and vertigo, what is the likely diagnosis and appropriate treatment?

Levetiracetam-Induced Vestibular Toxicity (Drug-Related Vertigo)

The most likely diagnosis is levetiracetam-induced vestibular toxicity causing vertigo and dizziness, and the treatment is to discontinue levetiracetam and switch to an alternative antiepileptic medication.

Diagnosis

This patient's temporal relationship between starting levetiracetam one week ago and developing new-onset vertigo ("room spinning sensation") and dizziness strongly suggests drug-induced vestibular toxicity. The FDA drug label explicitly lists dizziness (9% incidence) and vertigo (3% incidence) as known adverse effects of levetiracetam 111. These neurological adverse effects typically manifest within the first 4 weeks of treatment 1.

Key Diagnostic Features:

• Temporal correlation: Symptoms began 1 week after levetiracetam initiation
• Known adverse effect: Vertigo and dizziness are documented side effects occurring in 3-9% of patients 11
• Dose relationship: Patient is on 500 mg twice daily (1000 mg/day total), within the therapeutic range where these effects occur
• Previous stability: Patient was stable on phenytoin without these symptoms

Differential Considerations:

While benign paroxysmal positional vertigo (BPPV) could cause similar symptoms, the timing immediately following medication change makes drug-induced vestibular toxicity the primary diagnosis. Phenytoin toxicity can also cause vertigo and ataxia 23, but this is unlikely given the recent switch away from phenytoin.

Treatment Algorithm

Immediate Management:

1. Discontinue levetiracetam immediately - The drug is the likely causative agent based on temporal relationship and known adverse effect profile 11

2. Switch to alternative antiepileptic medication:

   • First choice: Valproate (20-30 mg/kg loading dose, then maintenance dosing)
   • Alternative: Fosphenytoin (if no prior phenytoin toxicity concerns)
   • Both have similar efficacy per 2024 ACEP guidelines 444

3. Symptomatic management:

   • Antiemetics if nausea/vomiting present
   • Fall precautions (vestibular symptoms increase fall risk)
   • Avoid activities requiring balance until symptoms resolve

Expected Timeline:

Levetiracetam-induced adverse effects typically resolve within 3-4 months after medication discontinuation or dose adjustment 5. However, improvement should begin within days to weeks of stopping the medication.

Clinical Reasoning

The 2024 ACEP guidelines establish that levetiracetam, fosphenytoin, and valproate have equivalent efficacy (approximately 45-47% seizure cessation rate) for status epilepticus 4444. However, the guidelines also note important safety differences:

• Levetiracetam: 0.7% hypotension rate, but notable neuropsychiatric effects 4
• Fosphenytoin: 3.2% hypotension rate 4
• Valproate: 1.6% hypotension rate, can cause dizziness but less vestibular toxicity 6

Recent systematic reviews confirm that levetiracetam carries significant risk of somnolence (OR 1.61) and neuropsychiatric adverse effects compared to placebo 7. Vestibular symptoms including vertigo, dizziness, and ataxia are well-documented with antiepileptic drugs, particularly levetiracetam 35.

Critical Pitfalls to Avoid

1. Do not continue levetiracetam hoping symptoms will resolve - Vestibular toxicity can persist and worsen, increasing fall risk and injury 23

2. Do not add vestibular suppressants without addressing the underlying cause - This masks the problem without solving it

3. Do not assume BPPV without considering medication timing - The one-week temporal relationship to drug initiation is too coincidental

4. Do not abruptly stop all antiepileptic medications - Switch to alternative agent to maintain seizure control

5. Monitor for seizure recurrence during medication transition - The patient has a known seizure disorder requiring continuous treatment

Safety Considerations

The FDA drug label warns that levetiracetam may cause dizziness and somnolence, and patients should be advised not to drive or operate machinery until they understand how the medication affects them 1. The development of vertigo represents a clinically significant adverse effect warranting medication change, particularly given the availability of equally effective alternatives with different side effect profiles 444.